Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 8, 2014, Pages 1787-1798

  Knuschke, Torben ^a   Bayer, Wibke ^a   Rotan, Olga ^b   Sokolova, Viktoriya ^b   Wadwa, Munisch ^a   Kirschning, Carsten J ^a   Hansen, Wiebke ^a   Dittmer, Ulf ^a   Epple, Matthias ^b   Buer, Jan ^a   Westendorf, Astrid M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Delivery system; Nanoparticle; Retrovirus; T cell immunity; Vaccination

Indexed keywords

CALCIUM PHOSPHATE; CYTOLOGY; DISEASES; EPITOPES; IMMUNIZATION; MAMMALS; NANOPARTICLES; PEPTIDES; T-CELLS; VACCINES; VIRUSES;

ANTIGEN PRESENTING CELLS; CALCIUM PHOSPHATE NANOPARTICLES; DELIVERY SYSTEMS; PROTECTIVE IMMUNITIES; RETROVIRAL INFECTIONS; RETROVIRUS; VACCINATION; VACCINE DELIVERY SYSTEM;

IMMUNE SYSTEM;

CALCIUM PHOSPHATE; CPG OLIGODEOXYNUCLEOTIDE; EPITOPE; NANOPARTICLE; PEPTIDE VACCINE; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EFFECTOR CELL; FRIEND LEUKEMIA VIRUS; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; RETROVIRUS INFECTION; T LYMPHOCYTE; VACCINATION; VIRUS IMMUNITY; VIRUS LOAD; ANIMAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINE; CHEMISTRY; FLOW CYTOMETRY; IMMUNOLOGY; RETROVIRIDAE INFECTIONS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; FLOW CYTOMETRY; IMMUNITY, CELLULAR; MICE; NANOPARTICLES; RETROVIRIDAE INFECTIONS; VACCINES, SUBUNIT;

EID: 84908596828     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.06.014     Document Type: Article

References (50)

1. Storni T., Kundig T.M., Senti G., Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 2005, 57:333-355.
2. Riehemann K., Schneider S.W., Luger T.A., Godin B., Ferrari M., Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed Engl 2009, 48:872-897.
3. Zolnik B.S., Gonzalez-Fernandez A., Sadrieh N., Dobrovolskaia M.A. Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.
4. Correia-Pinto J.F., Csaba N., Alonso M.J. Vaccine delivery carriers: insights and future perspectives. Int J Pharm 2013, 440:27-38.
5. Cubas R., Zhang S., Kwon S., Sevick-Muraca E.M., Li M., Chen C., et al. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 2009, 32:118-128.
6. Canton I., Battaglia G. Endocytosis at the nanoscale. Chem Soc Rev 2012, 41:2718-2739.
7. Dane K.Y., Nembrini C., Tomei A.A., Eby J.K., O'Neil C.P., Velluto D., et al. Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival. J Control Release 2011, 156:154-160.
8. Sokolova V., Knuschke T., Kovtun A., Buer J., Epple M., Westendorf A.M. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials 2010, 31:5627-5633.
9. Knuschke T., Sokolova V., Rotan O., Wadwa M., Tenbusch M., Hansen W., et al. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol 2013, 190:6221-6229.
10. Fuse S., Molloy M.J., Usherwood E.J. Immune responses against persistent viral infections: possible avenues for immunotherapeutic interventions. Crit Rev Immunol 2008, 28:159-183.
11. Cervantes-Barragan L., Lewis K.L., Firner S., Thiel V., Hugues S., Reith W., et al. Plasmacytoid dendritic cells control T-cell response to chronic viral infection. Proc Natl Acad Sci U S A 2012, 109:3012-3017.
12. von Herrath M.G., Berger D.P., Homann D., Tishon T., Sette A., Oldstone M.B. Vaccination to treat persistent viral infection. Virology 2000, 268:411-419.
13. Zhao Z., Leong K.W. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci 1996, 85:1261-1270.
14. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
15. Altfeld M., Allen T.M. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol 2006, 27:504-510.
16. Gandhi R.T., Walker B.D. Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection. Curr Opin Immunol 2002, 14:487-494.
17. Wherry E.J., Blattman J.N., Ahmed R. Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol 2005, 79:8960-8968.
18. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003, 198:1909-1922.
19. Hasenkrug K.J., Dittmer U. Immune control and prevention of chronic Friend retrovirus infection. Front Biosci 2007, 12:1544-1551.
20. Zelinskyy G., Dietze K.K., Husecken Y.P., Schimmer S., Nair S., Werner T., et al. The regulatory T-cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus-specific cytotoxic T-cell response. Blood 2009, 114:3199-3207.
21. Chen W., Qin H., Chesebro B., Cheever M.A. Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol 1996, 70:7773-7782.
22. Antunes I., Tolaini M., Kissenpfennig A., Iwashiro M., Kuribayashi K., Malissen B., et al. Retrovirus-specificity of regulatory T cells is neither present nor required in preventing retrovirus-induced bone marrow immune pathology. Immunity 2008, 29:782-794.
23. Sokolova V., Knuschke T., Buer J., Westendorf A.M., Epple M. Quantitative determination of the composition of multi-shell calcium phosphate-oligonucleotide nanoparticles and their application for the activation of dendritic cells. Acta Biomater 2011, 7:4029-4036.
24. Bayer W., Schimmer S., Hoffmann D., Dittmer U., Wildner O. Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies. Vaccine 2008, 26:716-726.
25. Chesebro B., Wehrly K., Stimpfling J. Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med 1974, 140:1457-1467.
26. Robertson M.N., Miyazawa M., Mori S., Caughey B., Evans L.H., Hayes S.F., et al. Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods 1991, 34:255-271.
27. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997, 90:3245-3287.
28. Hasenkrug K.J., Brooks D.M., Dittmer U. Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 1998, 72:6559-6564.
29. Dietze K.K., Zelinskyy G., Gibbert K., Schimmer S., Francois S., Myers L., et al. Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci U S A 2011, 108:2420-2425.
30. Cohen J. Public health. AIDS vaccine trial produces disappointment and confusion. Science 2003, 299:1290-1291.
31. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
32. Armstead A.L., Li B. Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomedicine 2011, 6:3281-3293.
33. Mamo T., Moseman E.A., Kolishetti N., Salvador-Morales C., Shi J., Kuritzkes D.R., et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) 2010, 5:269-285.
34. Dorozhkin S.V., Epple M. Biological and medical significance of calcium phosphates. Angew Chem Int Ed Engl 2002, 41:3130-3146.
35. Sokolova V.V., Radtke I., Heumann R., Epple M. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials 2006, 27:3147-3153.
36. Sheng K.C., Kalkanidis M., Pouniotis D.S., Esparon S., Tang C.K., Apostolopoulos V., et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol 2008, 38:424-436.
37. de Titta A., Ballester M., Julier Z., Nembrini C., Jeanbart L., van der Vlies A.J., et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A 2013, 110:19902-19907.
38. Knuschke T., Epple M., Westendorf A.M. The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization. Hum Vaccin Immunother 2013, 10:1-6.
39. Krieg A.M. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther 2012, 22:77-89.
40. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009, 61:248-255.
41. Krishnamachari Y., Salem A.K. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 2009, 61:205-217.
42. Gibbert K., Dietze K.K., Zelinskyy G., Lang K.S., Barchet W., Kirschning C.J., et al. Polyinosinic-polycytidylic acid treatment of Friend retrovirus-infected mice improves functional properties of virus-specific T cells and prevents virus-induced disease. J Immunol 2010, 185:6179-6189.
43. Sokolova V., Knuschke T., Kovtun A., Buer J., Epple M., Westendorf A.M. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials 2010, 31:5627-5633.
44. Dittmer U., Brooks D.M., Hasenkrug K.J. Protection against establishment of retroviral persistence by vaccination with a live attenuated virus. J Virol 1999, 73:3753-3757.
45. Robertson M.N., Spangrude G.J., Hasenkrug K., Perry L., Nishio J., Wehrly K., et al. Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol 1992, 66:3271-3277.
46. Nair S., Bayer W., Ploquin M.J., Kassiotis G., Hasenkrug K.J., Dittmer U. Distinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse model. Retrovirology 2011, 8:76.
47. Bayer W., Lietz R., Ontikatze T., Johrden L., Tenbusch M., Nabi G., et al. Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology 2011, 8:75.
48. Zou W. Regulatory T, cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
49. Zelinskyy G., Kraft A.R., Schimmer S., Arndt T., Dittmer U. Kinetics of CD8+ effector T cell responses and induced CD4+ regulatory T cell responses during Friend retrovirus infection. Eur J Immunol 2006, 36:2658-2670.
50. Nilsson J., Boasso A., Velilla P.A., Zhang R., Vaccari M., Franchini G., et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006, 108:3808-3817.